Synbiotic containing extensively hydrolyzed formula improves gastrointestinal and atopic symptom severity, growth, caregiver quality of life, and hospital‐related healthcare use in infants with cow's milk allergy

Immunity, Inflammation and Disease

Catherine Casewell¹  Lisa Cooke²  Sarah Donohoe³  Sonia Armstrong³  Victoria Steele³  Devasmitha Venkataraman³  Rebecca J. Stratton⁴  Robert M. Browne⁴  Gary P. Hubbard⁴  Fiona J. Kinnear⁴  Kiranjit Atwal⁴  Abbie L. Cawood⁴  Rachel Vallis⁵  Debbie Evans⁵  Joan Gavin⁶  Sally‐Ann Denton⁶  Ailsa J. McHardy⁶  Lynne Graham⁷  Sankara Narayanan⁷ 

[1] Ashford and St Peter's Hospital NHS Foundation Trust Chertsey UK;Bristol Royal Hospital for Children Bristol UK;James Cook Hospital, South Tees Hospitals NHS Foundation Trust Middlesbrough UK;Nutricia Ltd Trowbridge UK;Royal Surrey NHS Foundation Trust Guildford UK;University Hospitals Southampton NHS Foundation Trust Southampton UK;West Hertfordshire Hospitals NHS Trust Watford UK;

关键词: cow's milk allergy;    dermatitis;    prebiotics;    probiotics;    synbiotics;   

DOI  :  10.1002/iid3.636

来源: DOAJ

【 摘 要 】

Abstract Background Healthy gut microbiota is important for prognosis in cow's milk allergy (CMA). The application of synbiotics (specific pre‐ and probiotics) in extensively hydrolyzed formulae (eHFs) is a relatively new concept. Aims To evaluate a synbiotic‐containing, whey‐based eHF (SeHF) with galacto‐oligosaccharides, fructo‐oligosaccharides, and bifidobacterium breve M‐16V in infants with CMA. Materials and Methods A 31‐day one‐arm pilot study in 29 infants with CMA (mean age 30.8 weeks [SD 11]) was undertaken, with outcomes including gastrointestinal tolerance, atopic dermatitis symptoms, dietary intake, growth, SeHF acceptability, caregiver quality of life, and hospital‐related healthcare use. Results Significant improvements (p < .05) in the severity of abdominal pain (in 57%), burping (in 46%), flatulence (in 79%), constipation (in 14%), rhinitis (41%), and itchy eyes (73%), as well as atopic dermatitis in those with severe baseline symptoms (PO‐SCORAD© reduction: 34.7–18.2 (p = .003), n = 6) were observed over time. Growth and caregiver quality of life scores significantly increased (+26.7%, p < .05) over time. Hospital visits and medications significantly reduced (−1.61 and −2.23, respectively, p < .005) in the 6 months after SeHF initiation. Discussion In this small, single‐arm, pilot study, the use of SeHF enhanced the management of infants with non‐IgE mediated CMA who were already established on eHF. Conclusion: Whilst this study adds to the evidence base for the use of SeHF in CMA, further robust research to explore the longer‐term benefits of synbiotics, specifically the blend used in this study, for the clinical management of infants with CMA is warranted.

【 授权许可】

Unknown